Ignite Creation Date:
2024-05-06 @ 12:14 PM
Last Modification Date:
2024-10-26 @ 12:56 PM
Study NCT ID:
NCT03711032
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2018-10-15
Brief Title:
Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Bacillus Calmette-Guerin BCG in High-Risk Non-Muscle Invasive Bladder Cancer HR NMIBC MK-3475-676KEYNOTE-676
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-12-24
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-10-12
Completion Date Type:
ESTIMATED
First Submit Date:
2018-10-15
First Submit QC Date:
October 16 2018
Study First Post Date:
2018-10-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-14
Last Update Post Date:
2024-07-05
Last Update Post Date Type:
ACTUAL